XENON PHARMACEUTICALS INC. Long-Term Debt, Maturity, Year Five
XENON PHARMACEUTICALS INC. (XENE) had Long-Term Debt, Maturity, Year Five of $4.13 million as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2018-11-06
- 2018-09-30: Long-Term Debt, Maturity, Year Five $4.13M.
- 2018-06-30: Long-Term Debt, Maturity, Year Five $3.60M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2018-09-30 | $4.13M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $3.60M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |